diaDexus licenses colorectal cancer test to Quest:
This article was originally published in Clinica
diaDexus has licensed its proprietary genomics-based test for the detection of colorectal cancer to Quest Diagnostics. Quest has exclusive rights to develop and commercialise the test in its laboratories in the US and in certain international markets. South San Francisco, California-based diaDexus receives an upfront licensing fee and royalties. It also gets the rights to develop a test for certain markets in the future. The non-invasive test detects Reg-4, a protein that has been implicated in colorectal cancer and could be an important tool for early detection.